Rare Disease Day, Zevra Therapeutics
Arrowhead, Zevra fire up campaigns for Rare Disease Day 2025
Zevra used the awareness day to roll out the “Learn NPC, Read Between the Signs” disease awareness campaign. The biotech won FDA approval for a Niemann-Pick disease type C (NPC) treatment, Miplyffa, last year and recently agreed to sell a priority review voucher for $150 million to fund the launch and other work.
LaDuane Clifton, Zevra’s Chief Financial Officer said, “This non-dilutive capital strengthens our balance sheet by adding gross cash proceeds of $150 million, supporting continued investment in our ...
For Zevra Therapeutics, last year’s approval of the rare lysosomal storage disorder drug Miplyffa appears to be the gift that ...
Rare disease-focused biopharma Zevra Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to an undisclosed buyer for $150 million.
Timothy J. Sangiovanni, Senior Vice President of Finance and Corporate Controller at Zevra Therapeutics Inc. (NASDAQ:ZVRA), ...
ZEVRA THERAPEUTICS ($ZVRA) is expected to release its quarterly earnings data on Friday, February 28th after market close, per Finnhub. Analysts are expecting revenue ...
Investing.com -- Shares of Zevra Therapeutics, Inc. ( Nasdaq: ZVRA) climbed 8% following the announcement that the company has entered into an agreement to sell its Rare Pediatric Disease Priority ...
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of ...
Zevra Therapeutics, Inc. announced that it will receive a 2025 New Treatment Award for its product MIPLYFFA™ (arimoclomol) at the 21st Annual WORLDSymposium. Eight abstracts related to MIPLYFFA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback